What's Happening?
Lisa Schmitz Mazur, a partner at McDermott Will & Emery LLP based in Chicago, specializes in health law, focusing on the intersection of healthcare and technology, known as 'digital health.' Her practice involves advising various healthcare providers
and technology companies on the legal and regulatory frameworks governing digital health solutions. This includes areas such as telehealth, telemedicine, mobile health, and consumer wellness programs. Mazur assists clients in developing and implementing telemedicine programs by providing guidance on critical issues like professional licensure, scope of practice, informed consent, prescribing practices, and reimbursement. She also helps clients navigate the complex and evolving regulatory landscape of digital health, ensuring they develop practical and forward-thinking strategies. Her work extends to advising hospitals and health systems on corporate governance, tax-exemption issues, conflict of interest compliance, and overall corporate compliance effectiveness. Additionally, she assists in developing and negotiating physician compensation programs and preparing agreements with physicians.
Why It's Important?
Mazur's work is crucial for the U.S. healthcare industry as it grapples with the rapid expansion of digital health technologies. Her expertise helps healthcare providers and technology companies comply with intricate regulations, thereby mitigating legal risks and fostering innovation in patient care delivery. The increasing adoption of telemedicine and mobile health solutions, accelerated by recent global health events, necessitates clear legal guidance to ensure patient safety, data privacy, and equitable access to care. By advising on professional licensure and reimbursement, Mazur directly impacts the operational viability and scalability of digital health services, which can significantly reduce healthcare costs and improve access for underserved populations. Her involvement in corporate governance and compliance for hospitals also ensures the ethical and legal functioning of major healthcare institutions, safeguarding public trust and financial stability within the sector.
What's Next?
As digital health continues to evolve, the demand for specialized legal counsel like Mazur's is expected to grow. Future developments will likely include further refinement of regulations concerning data privacy, cybersecurity, and the integration of artificial intelligence in healthcare. Mazur will likely continue to guide clients through these emerging challenges, helping them adapt to new legal requirements and technological advancements. The ongoing expansion of telehealth services, particularly across state lines, will require continuous legal interpretation and strategic planning regarding licensure and reimbursement models. Additionally, as new digital health products and services enter the market, her role in ensuring compliance with existing and forthcoming regulations will be vital for their successful implementation and adoption within the U.S. healthcare system.
Beyond the Headlines
The broader implications of Mazur's work touch upon the ethical considerations of digital health, particularly regarding patient data ownership, algorithmic bias in AI-driven diagnostics, and the digital divide in access to technology. As healthcare becomes increasingly digitized, questions of equity and accessibility for all demographic groups become paramount. Mazur's guidance on informed consent and compliance helps ensure that technological advancements do not inadvertently create new barriers to care or compromise patient autonomy. Her role also highlights the growing need for interdisciplinary collaboration between legal experts, technologists, and healthcare professionals to shape a future where digital health solutions are both innovative and ethically sound. The legal frameworks she helps establish will influence how personal health information is protected and how new medical technologies are integrated into daily practice, ultimately shaping the future of healthcare delivery in the U.S.
